Elanco Animal Health to Acquire Kindred Biosciences

Merck Animal Health to acquire Elanco's aqua business for ~$1.3B

February 6, 2024

Veterinary

Merck Animal Health has agreed to buy Elanco Animal Health's aqua business for approximately US$1.3 billion in cash. The divestiture — which includes marketed brands, R&D projects, manufacturing sites in Prince Edward Island (Canada) and Dong Nai (Vietnam), and roughly 280 commercial and manufacturing employees — will allow Elanco to focus on higher-growth pet and livestock markets and use proceeds to pay down debt.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Merck to Acquire Acceleron Pharma Inc for $11.5B

September 30, 2021

Biotechnology

Merck (through a subsidiary) entered into a definitive agreement to acquire Acceleron Pharma Inc for $180 per share in cash, for an approximate total equity value of $11.5 billion. The transaction will be completed via a tender offer followed by a merger, and is expected to close in the fourth quarter of 2021, subject to conditions including regulatory approvals and tender of at least a majority of outstanding shares.

LifePoint Health Acquires Kindred Healthcare

June 21, 2021

Healthcare Services

LifePoint Health agreed to acquire Kindred Healthcare in June 2021 and completed the transaction in December 2021, combining LifePoint's community hospital network with Kindred's long-term acute care, rehabilitation and behavioral health capabilities. The deal created a new national system, ScionHealth, and LifePoint committed to invest roughly $1.5 billion over three years to expand services, technology and community-based care.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.

AbbVie to Acquire ImmunoGen for $10.1 Billion

November 30, 2023

Pharmaceuticals

AbbVie entered into a definitive agreement to acquire ImmunoGen, including its flagship ADC therapy ELAHERE (mirvetuximab soravtansine-gynx), in a deal valued at approximately $10.1 billion. The transaction is expected to close in mid-2024, subject to ImmunoGen shareholder approval, regulatory approvals, and other customary closing conditions.